Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Solid Tumors 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Hodgkin Disease 1Burkitt Lymphoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 8Vincristine 6Etoposide 5prednylidene 4deltacortene 4Specimen Handling 4Prednisone 4Methotrexate 4Doxorubicin 4pegaspargase 3merphos 3fludarabine phosphate 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Rituximab 3Magnetic Resonance Spectroscopy 3Dexamethasone 3Cytarabine 3Calcium Dobesilate 3venetoclax 2Whole-Body Irradiation 2Tacrolimus 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2Leucovorin 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2CT-P10 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × pegylated granulocyte colony-stimulating factor × 30 days × Clear all
NCT06738368 2026-05-12

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

University of Washington

Phase 2 Recruiting
30 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡